β-Escin overcomes trastuzumab resistance in HER2-positive breast cancer by targeting cancer stem-like features

BACKGROUND: The emergence of de novo or intrinsic trastuzumab resistance is exceedingly high in breast cancer that is HER2 positive and correlates with an abundant cancer stem cell (CSC)-like population. We sought to examine the capacity of β-escin, an anti-inflammatory drug, to address trastuzumab...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Soeun, Park, Jung Min, Park, Minsu, Ko, Dongmi, Kim, Seongjae, Seo, Juyeon, Nam, Kee Dal, Jung, Eunsun, Farrand, Lee, Kim, Yoon-Jae, Kim, Ji Young, Seo, Jae Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9490928/
https://www.ncbi.nlm.nih.gov/pubmed/36127671
http://dx.doi.org/10.1186/s12935-022-02713-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9490928/
https://www.ncbi.nlm.nih.gov/pubmed/36127671
http://dx.doi.org/10.1186/s12935-022-02713-9

Ejemplares similares